TT32

TT32 is a recombinant fusion protein designed to modulate the complement system, initially developed by Alexion Pharmaceuticals. The molecule consists of the first ten short consensus repeats (SCRs) of complement receptor 1 (CR1) fused to a targeting domain derived from complement receptor 2 (CR2). This design allows TT32 to specifically target tissues where complement has been activated by binding to deposited C3 fragments via the CR2 domain. Once localized, the CR1 portion of the fusion protein inhibits both the classical and alternative complement pathways by providing decay-accelerating activity and acting as a cofactor for the cleavage of C3 and C5 convertases. Preclinical research has demonstrated that TT32 significantly reduces clinical disease activity and inflammation in animal models of rheumatoid arthritis, including collagen-induced arthritis (CIA) and collagen antibody-induced arthritis (CAIA).

Other names

CR2-CR1 fusion proteinCR-2-CR1 fusion proteinCR 2-CR1 fusion protein